<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001374</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-0769</org_study_id>
    <nct_id>NCT04001374</nct_id>
  </id_info>
  <brief_title>Platelet Sub-study of the TWILIGHT Trial</brief_title>
  <official_title>Platelet Sub-study of the TWILIGHT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan Badimon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TWILIGHT study is a multicenter RCT comparing treatment with ticagrelor alone versus
      ticagrelor plus aspirin in high-risk patients after PCI. All patients will receive DAPT
      (ticagrelor plus aspirin) for the initial 3 months post-PCI and then be randomized to either
      Ticagrelor alone OR Ticagrelor plus Aspirin DAPT.

      To investigate the pharmacodynamic effects of the two treatments in this trial, a 'Platelet
      Sub-study' will be conducted only at the Mount Sinai Medical Center. The sub-study will
      recruit randomized patients from the TWILIGHT Trial at Mount Sinai and conduct specialized
      blood tests at randomization and one month thereafter. The aim of the Platelet Sub-study is
      to compare the antithrombotic effects of Ticagrelor alone versus Ticagrelor plus Aspirin
      using an ex vivo model of thrombosis (Badimon Chamber).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study will enroll a cohort of randomized patients from the TWILIGHT trial at the
      Mount Sinai Medical Center. These subjects will undergo blood sampling and measurement of
      thrombotic indices at the time of randomization and 1-6 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2015</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombus size (Badimon Chamber)</measure>
    <time_frame>1-6 months after randomization</time_frame>
    <description>Thrombus area measured 1-6 months after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>1-6 months after randomization</time_frame>
    <description>Platelet aggregation assessed using Multiplate Analyzer 1-6 months after randomization</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <description>Ticagrelor 90mg tablet bid for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor + ASA</arm_group_label>
    <description>Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90mg tablet bid for 12 months</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_label>Ticagrelor + ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months</description>
    <arm_group_label>Ticagrelor + ASA</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Randomized subjects from the TWILIGHT trial treated at Mount Sinai Medical Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients enrolled in the TWILIGHT trial:

        Clinical Inclusion Criteria (must meet at least one):

          -  Adult patients ≥ 65 years of age

          -  Troponin (+) acute coronary syndrome

          -  Female gender

          -  Established vascular disease defined as previous MI, documented PAD or CAD/PAD
             revascularization

          -  Diabetes mellitus treated with medications (oral hypoglycemic, subcutaneous injection
             of insulin)

          -  Chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) &lt; 60
             ml/min/1.73m2 or creatinine clearance (CrCl) &lt; 60 ml/min

        Angiographic Inclusion Criteria (must meet at least one):

          -  Multivessel coronary artery disease

          -  Target lesion requiring total stent length &gt;30 mm

          -  Thrombotic target lesion(s)

          -  Bifurcation lesions with Medina X,1,1 classification requiring at least 2 stents

          -  Left main (≥50%) or proximal LAD (≥70%) lesion

          -  Calcified target lesion(s) requiring atherectomy

        Exclusion Criteria:

        Patients not eligible to participate in the TWILIGHT trial:

          -  Under 18 years of age

          -  Contraindication to aspirin

          -  Contraindication to ticagrelor

          -  Planned surgery within 90 days

          -  Planned coronary revascularization (surgical or percutaneous) within 90 days

          -  Need for chronic oral anticoagulation

          -  Prior stroke

          -  Dialysis-dependent renal failure

          -  Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease,
             gastrointestinal pathology with a raised risk for bleeding, malignancies with a raised
             risk for bleeding)

          -  Emergent or salvage PCI or STEMI presentation.

          -  Liver cirrhosis

          -  Life expectancy &lt; 1 year

          -  Unable or unwilling to provide informed consent

          -  Women of child bearing potential (as determined by hospital standard of care)

          -  Fibrinolytic therapy within 24 hours of index PCI

          -  Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer

          -  Platelet count &lt; 100,000 mm3

          -  Requiring ongoing treatment with aspirin &gt; 325 mg daily.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Badimon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, Farhan S, Gurbel P, Gibson CM, Fuster V, Mehran R, Badimon JJ. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll Cardiol. 2020 Feb 18;75(6):578-586. doi: 10.1016/j.jacc.2019.11.056.</citation>
    <PMID>32057371</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Juan Badimon</investigator_full_name>
    <investigator_title>Professor of Medicine and Director of AtheroThrombosis Research Lab</investigator_title>
  </responsible_party>
  <keyword>Thrombosis</keyword>
  <keyword>Platelets</keyword>
  <keyword>Platelet Aggregation</keyword>
  <keyword>Blood Thrombogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

